Finanzen von Janux Therapeutics Inc (JANX)JANXJanux Therapeutics Inc

Evaluating the bottom line, Janux Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -308.66%, while the net margin is -214.01%. These profitability ratios, combined with a Return on Equity (ROE) of -10.70%, provide a clear picture of how effectively JANX converts its operational activities into shareholder value.

In the context of the broader market, JANX competes directly with industry leaders such as KURA and GLUE. With a market capitalization of $1.15B, it holds a significant position in the sector. When comparing efficiency, JANX's gross margin of 100.00% stands against KURA's 98.84% and GLUE's 100.00%. Such benchmarking helps identify whether Janux Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Janux's recent financial performance shows significant losses, with a net income of -$21,972,000 for Q2 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near term. The gross margin remains strong at 100% for recent quarters, but overall revenue generation is inconsistent.